These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31903928)

  • 21. Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations.
    Pivot X; Aulagner G; Blay JY; Fumoleau P; Kaliski A; Sarkozy F; Limat S
    Anticancer Drugs; 2015 Nov; 26(10):1009-16. PubMed ID: 26352219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biosimilars in Oncology in the United States: A Review.
    Nabhan C; Parsad S; Mato AR; Feinberg BA
    JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.
    Thill M
    Expert Rev Anticancer Ther; 2015 Mar; 15(3):331-8. PubMed ID: 25539719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrating trastuzumab biosimilars and HER2-directed therapies into HER2-positive breast cancer management.
    Cuellar S
    Am J Manag Care; 2020 Mar; 26(2 Suppl):S32-S40. PubMed ID: 32282173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of the trastuzumab biosimilar candidate CT-P6.
    Esteva FJ; Saeki T; Kim H; Stebbing J
    Future Oncol; 2018 Aug; 14(19):1909-1919. PubMed ID: 29482364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomised clinical endpoint studies for trastuzumab biosimilars: a systematic review.
    Coory M; Thornton K
    Breast Cancer Res Treat; 2019 Jul; 176(1):17-25. PubMed ID: 30980209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trastuzumab in Breast Cancer Treatment: The Era of Biosimilars.
    Peliçário Vargas B; Sari MHM; Ferreira LM
    Anticancer Agents Med Chem; 2022; 22(14):2507-2516. PubMed ID: 35236272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterizing experiences of non-medical switching to trastuzumab biosimilars using data from internet-based surveys with US-based oncologists and breast cancer patients.
    Papautsky EL; Carlson M; Johnson SM; Montague H; Attai DJ; Lustberg MB
    Breast Cancer Res Treat; 2022 Jul; 194(1):25-33. PubMed ID: 35568748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on biosimilars in rheumatology.
    Rischin A; Östör AJ
    Inflammopharmacology; 2017 Apr; 25(2):177-184. PubMed ID: 28265837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence.
    Jacobs I; Ewesuedo R; Lula S; Zacharchuk C
    BioDrugs; 2017 Feb; 31(1):1-36. PubMed ID: 28078656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.
    Chai Q; Wen H; Lang Y; Zhang L; Song Y; Liu X
    Clin Drug Investig; 2022 Nov; 42(11):937-947. PubMed ID: 36115003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biosimilars in rheumatology: the wind of change.
    Schneider CK
    Ann Rheum Dis; 2013 Mar; 72(3):315-8. PubMed ID: 23390018
    [No Abstract]   [Full Text] [Related]  

  • 34. [Biosimilar drugs in oncology].
    Levêque D
    Bull Cancer; 2016 Mar; 103(3):294-8. PubMed ID: 26832422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trastuzumab biosimilar in metastatic breast cancer: Evaluating equivalence with originator using network meta-analysis
.
    Mengato D; Chiumente M; Messori A
    Int J Clin Pharmacol Ther; 2019 Mar; 57(3):160-162. PubMed ID: 30574866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trial Validates Biosimilar for Trastuzumab.
    Cancer Discov; 2016 Jul; 6(7):686-7. PubMed ID: 27277256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progress in oncology biosimilars till 2020: Scrutinizing comparative studies of biosimilar monoclonal antibodies.
    Safdar A; Butt MH; Ahmad A; Zaman M
    J Oncol Pharm Pract; 2021 Jul; 27(5):1195-1204. PubMed ID: 34096401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Webinar as an Informational Resource on Trastuzumab Biosimilars: Planning, Promotion, Execution, and Evaluation.
    Papautsky EL; Carlson M; Johnson SM; Montague H; Valero L; Attai DJ; Harvey RD; Lyman GH; Lustberg M
    Cancer Invest; 2022 Aug; 40(7):654-662. PubMed ID: 35770934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biosimilars: what the oncologist should know.
    Thill M; Thatcher N; Hanes V; Lyman GH
    Future Oncol; 2019 Apr; 15(10):1147-1165. PubMed ID: 30793950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer.
    Blackwell K; Gligorov J; Jacobs I; Twelves C
    Clin Breast Cancer; 2018 Apr; 18(2):95-113. PubMed ID: 29525430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.